Manufactured Object
Predictive Analytics and AI: Reducing Emergency Room Visits through Enhanced Triage and Resource Allocation
Predictive analytics, Artificial intelligence (AI), Emergency department (ED) visits, Triage, Resource allocation, Machine learning (ML), Healthcare optimization
FDA Reconsiders Tirzepatide Shortage Status, Allowing Continued Compounding
Tirzepatide, FDA, drug shortage, compounding pharmacies, GLP-1 medications
HIV Prevention: A Proven Solution Eludes Many Due to Systemic Barriers
HIV Prevention, PrEP (Pre-Exposure Prophylaxis), Health Equity, Marginalized Communities, Stigma, Access to Healthcare
Eli Lilly Expands Global Footprint with £279 Million Investment in UK’s Biotech Sector
Eli Lilly, Gateway Labs, UK biotech, life sciences, Alzheimer’s treatment, donanemab, investment, healthcare innovation
FDA Reconsiders Removal of Eli Lilly’s Tirzepatide from Shortage List, Boosting Compounding Pharmacies
FDA, Eli Lilly, Tirzepatide, GLP-1 drug, Shortage list, Compounding pharmacies, Weight loss medication, Type 2 diabetes treatment
Eli Lilly Commits £279 Million to UK Life Sciences Sector in Groundbreaking Partnership
Eli Lilly, UK life sciences, £279 million investment, Lilly Gateway Labs, obesity treatment, UK government partnership
2024 Nobel Prize in Chemistry Awarded to Trio for Groundbreaking Protein Research
Nobel Prize in Chemistry 2024, Protein Structure Prediction, Computational Protein Design, David Baker, Demis Hassabis, John Jumper
Merck & Co. Partners with Mestag Therapeutics to Identify Novel Targets for Inflammatory Diseases
Mestag Therapeutics, Merck & Co., Inflammatory diseases, Fibroblast-immune interactions, RAFT platform, Therapeutic targets, Collaboration agreement
Compounding Pharmacies Challenge FDA’s Decision to End Eli Lilly’s GLP-1 Drug Shortage
Eli Lilly, GLP-1 drug, FDA, compounding pharmacies, drug shortage, lawsuit
Merck & Co. and Mestag Therapeutics Collaborate on $1.9 Billion Fibroblast Therapy Deal for Inflammatory Diseases
Merck & Co., Mestag Therapeutics, Fibroblast therapies, Inflammatory diseases, $1.9 billion deal, RAFT platform, Drug target identification